Press Releases

 
Press Releases
Date Title and Summary View
Nov 20, 2014 BARCELONA, Spain, Nov. 20, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) and Myriad Genetics (Nasdaq:MYGN) today announced a collaboration utilizing Myriad's myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, TESARO will utilize Myriad's test to enr...
Nov 19, 2014 SALT LAKE CITY, Nov. 19, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today presented new data that showed Vectra® DA is a better predictor of radiographic progression over two years than other tests used to assess risk of joint damage in rheumatoid arthritis (RA), such as C-r...
Nov 10, 2014 SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that new data on Vectra® DA will be featured at the 2014 American College of Rheumatology (ACR) Annual Meeting, Nov. 15-19, 2014, in Boston, Massachusetts. "Vectra DA is a game changer fo...
Nov 7, 2014 SALT LAKE CITY, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a prospective clinical utility study of its Myriad myPath Melanoma test at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a genetic test that differentiates malignant melan...
Nov 4, 2014 Revenue of $168.8 million; diluted EPS of $0.21; adjusted EPS of $0.25myRisk Hereditary Cancer revenue of $53.1 million, up 95 percent sequentiallyDraft Medicare decision covering Prolaris for low-risk prostate cancer patientsCHMP recommends approval of olaparib in ovarian cancer patients with BRCA mutationsCompany reiterates fiscal year 2015 finan...
Nov 3, 2014 SALT LAKE CITY, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an expanded companion diagnostic agreement with AbbVie, Inc. (NYSE:ABBV), a leading global biopharmaceutical company to use Tumor BRACAnalysis CDx™ as a companion diagnostic in support of AbbVie's novel poly (ADP-ribose) pol...
Oct 29, 2014 SALT LAKE CITY, Oct. 29, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the 2014 Credit Suisse Annual Healthcare Conference, at 3:00 p.m. Eastern on November 12, 2014, at the Arizona Biltmore Hotel in Phoenix, Arizona. The prese...
Oct 27, 2014 SALT LAKE CITY, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Prolaris test has been included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) for all men with localized prostate cancer, regardless of their risk category. The NCCN guidelines prov...
Oct 24, 2014 SALT LAKE CITY and ZURICH, Oct. 24, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has established a Tumor BRACAnalysis CDx laboratory in Europe. Myriad's next-generation Tumor BRACAnalysis CDx test is a companion diagnostic that will identify up to 50 percent more patients with BRAC mutations who may benefit from t...
Oct 21, 2014 SALT LAKE CITY, Oct. 21, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal first quarter 2015 following the close of market on Tuesday, November 4, 2014. The Company also will host a conference call at 4:30 p.m. ET on November 4, 2014 to discuss the financial results...
Page:
1
... NextLast
= add release to Briefcase